Astrazeneca Merck Face Nice Setback In Bid For Broader Lynparza Use | Latest News RSS feed

Astrazeneca Merck Face Nice Setback In Bid For Broader Lynparza Use - Latest News


AstraZeneca, Merck face NICE setback in bid for broader Lynparza use

AstraZeneca and Merck & Co.’s Lynparza recently put up ovarian cancer data that blew away pharma watchers at a European Society for Medical Oncology meeting, and it’s been broadening its reach with ne... read more

AstraZeneca's (AZN) CEO Pascal Soriot on Q4 2015 Results - Earnings Call Transcript

AstraZeneca PLC (NYSE:AZN) Q4 2015 Earnings Conference Call ... That doesn't have an impact on our core program in lung cancer but certainly is a setback from -- for this indication and also a setback ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us